Functional MMP-9 polymorphisms modulate plasma MMP-9 levels in multiple sclerosis patients

被引：18
|
作者：
da Silva Fernandes, Karla Simone [2 ,3 ]
Brum, Doralina Guimaraes [1 ]
Palei, Ana Carolina [2 ]
Sandrim, Valeria Cristina [3 ]
Guerreiro, Carlos Tostes [1 ]
Tanus-Santos, Jose Eduardo [2 ]
Barreira, Amilton Antunes [1 ]
机构：
[1] Univ Sao Paulo, Med Sch Ribeirao Preto, Dept Neurosci, BR-14049900 Ribeirao Preto, SP, Brazil
[2] Univ Sao Paulo, Med Sch Ribeirao Preto, Dept Pharmacol, BR-14049900 Ribeirao Preto, SP, Brazil
[3] Nucleo Posgrad & Pesquisa, Belo Horizonte, MG, Brazil
来源：
JOURNAL OF NEUROIMMUNOLOGY | 2012年 / 249卷 / 1-2期
关键词：
Multiple sclerosis; Degree of severity; Polymorphisms; MMP-9; Plasma; MATRIX-METALLOPROTEINASE (MMP)-9; GELATINASE B GENE; CEREBROSPINAL-FLUID; MATRIX-METALLOPROTEINASE-9; MMP-9; HEALTHY-SUBJECTS; INTERFERON-BETA; SERUM; TIMP-1; INHIBITORS; MRI;
D O I：
10.1016/j.jneuroim.2012.04.001
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
We have described that MMP-9 C- T-1562 and (CA)(n) polymorphisms contribute to multiple sclerosis (MS). Here, we evaluate whether plasma MMP-9 levels are related to disease severity, drug therapy resistance and polymorphisms. For sub-study 1, 36 patients with MS and 35 controls were recruited. For sub-study 2, 88 individuals (53 patients and 35 controls) were included in a cross-sectional analysis. MS patients presented higher MMP-9 activity (1.4 +/- 0.18 versus 0.93 +/- 0.18 A.U. for control, P<0.05). Drug-therapy resistant individuals exhibited increased MMP-9 activity (1.96 +/- 0.25 versus 1.21 +/- 0.09 A.U. for non-resistant patients). EDSS score was also related to MMP-9 levels. The CT + TT and HH genotypes had higher MMP-9 levels as compared to patients carrying the CC and LL Drug therapy resistance, disease severity. MMP-9 plasma activity and polymorphisms are associated with MS. (C) 2012 Elsevier B.V. All rights reserved.
引用
收藏
页码：56 / 59
页数：4
相关论文
共 50 条
  • [1] MMP-9 microsatellite polymorphism and multiple sclerosis
    Fiotti, N
    Zivadinov, R
    Altamura, N
    Nasuelli, D
    Bratina, A
    Tommasi, MA
    Bosco, A
    Locatelli, L
    Grop, A
    Cazzato, G
    Guarnieri, G
    Giansante, C
    Zorzon, M
    [J]. JOURNAL OF NEUROIMMUNOLOGY, 2004, 152 (1-2) : 147 - 153
  • [2] Functional polymorphisms in the promoter of the matrix metalloproteinase-9 (MMP-9) gene are not linked with significant plasma MMP-9 variations in healthy subjects
    Demacq, Caroline
    Vasconcellos, Vivian B.
    Marcaccini, Andrea M.
    Gerlach, Raquel F.
    Silva, Wilson A., Jr.
    Tanus-Santos, Jose E.
    [J]. CLINICAL CHEMISTRY AND LABORATORY MEDICINE, 2008, 46 (01) : 57 - 63
  • [3] Matrix metalloproteinase 9 (MMP-9) gene polymorphism and MMP-9 plasma levels in primary Sjogren's syndrome
    Hulkkonen, J
    Pertovaara, M
    Antonen, J
    Pasternack, A
    Hurme, M
    Pöllänen, P
    Lehtimäki, T
    [J]. RHEUMATOLOGY, 2004, 43 (12) : 1476 - 1479
  • [4] Plasma levels of TNF-α and MMP-9 in patients with silicosis
    Jiang, P. -R.
    Cao, Z.
    Qiu, Z. -L.
    Pan, J. -W.
    Zhang, N.
    Wu, Y. -F.
    [J]. EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 2015, 19 (09) : 1716 - 1720
  • [5] Higher plasma MMP-9 level in breast cancer patients with MMP-9 promoter T allele
    Hemati, Simin
    Sadeghi, Morteza
    Motovali-Bashi, Majid
    Sahebi, Ali
    Malekshahi, Ziba Vaise
    [J]. JOURNAL OF BIOLOGICAL RESEARCH-THESSALONIKI, 2010, 13 : 113 - 118
  • [6] MMP-9 overexpression as a result of MMP-9 intragenic hypermethylation
    Candido, Saverio
    Salemi, Rossella
    Falzone, Luca
    Malaponte, Grazia
    Scalisi, Aurora
    Libra, Massimo
    [J]. INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE, 2017, 40 : S44 - S44
  • [7] Association of MMP-9 gene polymorphisms with nephrolithiasis patients
    Mehde, Atheer Awad
    Mehdi, Wesen Adel
    Yusof, Faridah
    Raus, Raha Ahmed
    Abidin, Zaima Azira Zainal
    Ghazali, Hamid
    Abd Rahman, Azlina
    [J]. JOURNAL OF CLINICAL LABORATORY ANALYSIS, 2018, 32 (01)
  • [8] Decreased MMP-9 production in primary progressive multiple sclerosis patients
    Sastre-Garriga, J
    Comabella, M
    Brieva, L
    Rovira, A
    Tintoré, M
    Montalban, X
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2004, 10 (04) : 376 - 380
  • [9] Significance of MMP-9 expression and MMP-9 polymorphism in prostate cancer
    Schveigert, Diana
    Valuckas, Konstantinas Povilas
    Kovalcis, Viktorija
    Ulys, Albertas
    Chvatovic, Genovefa
    Didziapetriene, Janina
    [J]. TUMORI JOURNAL, 2013, 99 (04): : 523 - 529
  • [10] Expression of MMP-2 and MMP-9 in patients with multiple myeloma
    Skliris, A.
    Labropoulou, V.
    Carina, S.
    Magne, B.
    Karamanos, N.
    Papageorgakopoulou, N.
    Theocharis, A.
    [J]. FEBS JOURNAL, 2008, 275 : 240 - 240
12345